Monocentric retrospective cohort of 30,423 COVID-19 patients

Population and design: Monocentric cohort comparing COVID-19 patients exposed or not exposed to the treatment hydroxychloroquine (HCQ)+azithromycin (AZ) used as a standard of care in our center (Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Marseille, France). The inclusion period was from 2 March 2020 to 31 December 2021, with a follow-up period of 6 weeks.
Inclusion and exclusion criteria: Data included were those of patients ≥ 18 years of age with PCR-proven COVID-19 disease regardless of symptoms (asymptomatic or symptomatic) and treated in our centre, i.e. having had a medical examination by one of the doctors in our centre (Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Marseille, France) either as outpatients or as inpatients, i.e. hospitalized on the day of the visit in our outpatient unit following evaluation or directly transferred from another medical ward except intensive care unit. The reasons for exclusion were an erroneous patient identifi..., Data source
For inpatients: Between 03.03.20 and 12.03.2021, i.e. the first year of the epidemic, data were collected using the Electronic Patient Record. The DPI ‘”Dossier Patient Informatisé”) centralized all the medical information of a patient concerning his stays at the Assistance Publique - Hôpitaux de Marseille. During this input, a large amount of medical data concerning the treatment was collected (2799 patients). Between 13.03.21 and 31.12.2021, the data were extracted from the APHM administrative database (PASTEL). PASTEL does not contain medical data but only the following information: IPP (“Identifiant Permanent du Patient”) which is a unique identifier for each patient, age, sex, date of entry, the different services in which the patient may have been hospitalised and the date of discharge (1791 patients).
For the outpatients, the medical cards of the patients who came to the outpatient unit filled in by the medical staff (11,725 patients). The content of these medical for...,

研究人群与研究设计：本研究为单中心队列研究，对比了法国马赛地中海感染大学医院中心（Institut Hospitalo-Universitaire (IHU) Méditerranée Infection）收治的、暴露与未暴露于羟氯喹（hydroxychloroquine, HCQ）+阿奇霉素（azithromycin, AZ）治疗的新型冠状病毒肺炎（COVID-19）患者，该疗法为本中心的标准治疗方案。纳入周期为2020年3月2日至2021年12月31日，随访周期为6周。

纳入与排除标准：纳入数据为年龄≥18岁、经聚合酶链式反应（PCR）证实感染COVID-19的患者，无论有无症状（无症状或有症状），且在本中心接受诊疗——即经本中心医师完成门诊或住院检查的患者，包括在门诊评估后当日于本科室住院的患者，或直接从其他医疗科室（重症监护室除外）转诊入院的患者。排除原因为患者身份有误……

数据来源
对于住院患者：2020年3月3日至2021年3月12日（即疫情暴发首年），通过电子病历系统采集数据。法国公共援助-马赛医院（Assistance Publique - Hôpitaux de Marseille, APHM）的信息化患者档案系统（Dossier Patient Informatisé, DPI）集中存储了患者在该机构住院期间的全部医疗信息，此阶段共采集到2799例患者的大量治疗相关医疗数据。2021年3月13日至2021年12月31日期间，数据从APHM行政数据库（PASTEL）提取。PASTEL仅包含以下信息，不包含医疗数据：患者唯一识别码IPP（"Identifiant Permanent du Patient"）、年龄、性别、入院日期、患者曾住院的不同科室以及出院日期，此阶段共纳入1791例患者。

对于门诊患者，数据来自医护人员填写的门诊患者病历卡（共11725例患者）。该类病历的内容……